In partnership with patients, families and medical providers, the Consortium brings together gastroenterologists and scientists from academic centers worldwide to identify the causes of Very Early Onset Inflammatory Bowel Disease (VEO-IBD) and develop new treatments for children with these rare diseases.

Our research

The P4Care Portal stands for Pediatric (VEOIBD) Portal for Personalized Patient Care, illustrating the workflow of offering personalized care with 5 main steps:

  1. Phenotyping and Genotyping: VEOIBD patients inclusive of clinical metadata and immunologic data.
  2. Discovery: Utilizing and multi-omics, inclusive of genomics, transcriptomics, proteomics, organoid and metabolomic data.
  3. Functional studies and Experimental Validation Models: Using induced pluripotent stem cells and other cell lines, organoids, mice, zebrafish.
  4. Computational Biology & Integrative Analysis: Amalgamating the clinical metadata, multi-omic discoveries and functional studies in silico.
  5. Therapeutic Platform: Utilizing cell and gene therapy, biologics, small molecules to return precision-based therapeutic approaches back to the patients.

Patient enrollment enables us to:

  • Identify the genetic variants responsible for VEO-IBD and define the molecular networks which are disrupted as a result of these variants.
  • Create an innovative Pediatric VEO-IBD Portal for Personalized Patient Care (P4Care) to develop tailored treatments for VEO-IBD patients.
  • Determine environmental factors affecting genetic and immunologic pathways relevant to VEO-IBD.
three babies sitting over a circle labeled 1-5 clockwise